Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Strepsils; Belgium: Froben; Cyprus: Flurozin, Nibelon; Czech Republic: Strepfen; Denmark: Flurofen, Strepfen; Estonia: Strepsils Intensive; France: Antadys, Cebutid, Ocufen, Strefen; Germany: Dobendan Strepsils Direkt Flurbiprofen, Ocuflur; Greece: Eyeflur, Fluroptic, Kirik, Neliacan, Strepfen; Hungary: Flugalin, Strepfen; Ireland: Froben, Strepsils Intensive; Italy: Benactiv Gola, Flubifix, Flurbiprofene, Froben, Ocufen, Tantum Activ Gola, Transact Lat; Latvia: Strepsils Intensive; Lithuania: Strepsils Intensive; Netherlands: Froben; Poland: Ansaid, Flugalin, Strepsils Intensive; Portugal: Edolfene, Froben, Strepfen, Transact Lat; Romania: Strepsils Intensiv; Slovakia: Flugalin, Strepfen; Spain: Froben; UK: Froben, Ocufen, Strepfen.

North America

Canada: Ansaid, Flurbiprofen, Ocufen; USA: Ansiad, Flurbiprofen, Ocufen.

Latin America

Argentina: Clinadol Forte, Flurbic, Luarprofeno; Brazil: Ocufen, Targus Lat; Mexico: Ansiad, Ocufen.


Japan: Adofeed, Anmetarin, Falken, Flubinurse, Flupe, Froben, Fulruban, Ropion, Stayban, Upnon, Yakuban, Zepolas.

Drug combinations


Flurbiprofen Sodium: C~15~H~12~FNaO~2~ 2H~2~O. Mw: 302.27. (1) [1,1′-Biphenyl]-4-acetic acid, 2-fluoro-α-methyl, sodium salt dihydrate, (±)-; (2) Sodium (±)-2-(2-fluoro-4-biphenylyl)propionate dihydrate. CAS-56767-76-1.

Pharmacologic Category

Other Nonsteroidal Anti-inflammatory Agents. (ATC-Code: M01AE09; M02AA19; R02AX01; S01BC04).

Mechanism of action

Flurbiprofen, a propionic acid derivative, is a prototypical NSAID which also exhibits analgesic and antipyretic activity. It inhibits COX-1/PTGS1 and COX-2/PTGS2.

Therapeutic use

Oral treatment of rheumatoid arthritis and osteoarthritis. Inhibition of intraoperative miosis. Management of postoperative dental pain.

Pregnancy and lactiation implications

Teratogenic effects not observed in animal studies; however, adequate, well-controlled studies not conducted in pregnant women. Exposure late in pregnancy may lead to premature closure of the ductus arteriosus.

Unlabeled use


Hypersensitivity to flurbiprofen, aspirin, other NSAIDs, or any component of the formulation. Perioperative pain in the setting of CABG surgery.

Warnings and precautions

Anaphylactoid reactions might occur (avoid use in patients who experience asthma, bronchospasm, rhinitis, or urticaria with NSAID or aspirin therapy). Bleeding, hemostasis or anemia are possible (use caution in coagulation disorders or patients receiving anticoagulants). Increased risk of adverse cardiovascular thrombotic events, including MI, stroke, and new onset or worsening of pre-existing hypertension (use caution with fluid retention, heart failure, or hypertension). NSAIDs may increase risk of GI irritation, inflammation, ulceration, bleeding, and perforation (use caution with history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, elderly or debilitated patients). NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Do not administer to patients with aspirin-sensitive asthma, since severe bronchospasm may occur (use caution in other forms of asthma). Use is contraindicated for treatment of perioperative pain in the setting of CABG surgery. Use with caution in decreased hepatic function. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Not recommended for use in advanced renal disease. Long-term NSAID use may result in renal papillary necrosis. The elderly are at increased risk for adverse effects (especially peptic ulceration, CNS effects, renal toxicity) from NSAIDs, even at low doses. Withhold for at least 4-6 half-lives prior to surgical or dental procedures.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart